Document:

Exhibit 10.16

 

[               ]

 

[              ], 2017

 

RE: BeyondSpring
Inc. (the “Company”)

 

Dear [                   ],

 

I am writing to you on behalf of the board
of directors of the Company to confirm arrangements with regard to the terms of appointment to office as a director of the Company
from the date of this letter.

 

		1.	Definitions

 

For the purposes of this Letter, the following
words or expressions shall have the following meanings respectively:

 

	“Board”	means the board of directors of the Company, including any committee of the Board duly constituted by it;
	“Businesses”	means:
	 	(a)	
the business of the research,
development, design, production, manufacturing, marketing, sale, distribution and other commercial activities of any Group Company
in relation to the Group’s proprietary and/or licensed technology concerning the development of cancer therapies; and
	 	(b)	
        any other business that
any Group Company shall at the relevant date
	 	 	(i)	
        be engaged in
and with which you shall have been concerned or involved to any material extent at any time during Your Appointment; or
	 	 	(ii)	        have determined to carry on with a view to developing any other biotechnical technology for commercial exploitation in the future and in relation to which determination you shall at the Termination Date possess any material Confidential Business Information;
	 	 	 
	“Confidential Information”	means all and any Corporate Information, Marketing Information,
	 	Technical Information and other information (whether or not recorded in documentary form or on computer disk or tape) which the Company or any Group Company treats as confidential or in respect of which it owes an obligation of confidentiality to any third party, which is not in the public domain:
	 	(a)	
        which you shall have acquired
or shall hereafter acquire at any time during Your Appointment in your capacity as a director; and
	 	(b)	        which is not readily ascertainable to persons not connected with the Company or any Group Company
	

    	 

    	 

    

	 	 	 	 
	“Corporate Information”	means all and any information (whether or not recorded in documentary form or on computer disk or tape) relating to the business methods, corporate plans, management systems, finances, maturing new business opportunities or research and development projects of the Company or any Group Company;
	“Group”	means the Company and its affiliates, including any company that controls, is controlled by, or is under common control with the Company, as defined in Rule 3b-18 of the Securities Exchange Act of 1934, as amended from time to time;
	“Group Company”	means a member of the Group and “Group Companies” shall be interpreted accordingly;
	“Marketing Information”	means all and any information (whether or not recorded in documentary form or on computer disk or tape) relating to the marketing or sales of any past present or future product or service of the Company or any Group Company including, without limitation, sales targets and statistics, market share and pricing statistics, marketing surveys and plans, market research reports, sales techniques, price lists, discount structures, advertising and promotional material, the names, addresses, telephone numbers, contact names and identities of customers and potential customers of and suppliers and potential suppliers to the Company or any Group Company, the nature of their business operations, their requirements for any product or service sold to or purchased by the Company or any Group Company and all confidential aspects of their business relationship with the Company or any Group Company;
	“Material Interest”	means:
	 	(a)	
        the holding of any position
as director, officer, employee, consultant, partner, principal or agent;
	 	(b)	
        the direct or indirect
control or ownership (whether jointly or alone) of any shares (or any voting rights attached to them) or debentures save for the
ownership for investment purposes only of not more than five percent (5%) of the issued shares of any company whose shares are
listed on any national securities exchange (as defined in Section 3(a)(1) of the Securities Exchange Act of 1934, as amended from
time to time), or any similar exchange in jurisdictions outside the United States; or
	 	(c)	        the direct or indirect provision of any financing; other than on behalf of any Group Company for the legitimate purposes of that Group Company;
	“Technical Information”	means all and any trade secrets, secret formulae, processes, inventions, designs, know-how discoveries, technical specifications and other technical information (whether or not recorded in documentary form or on computer disk or tape) relating to the creation, production or supply of any past, present or future product or service of the Company or any Group Company;
	“Termination Date”	means the date of the termination of Your Appointment; and
	“Your Appointment”	means your appointment to and holding of office as a director of the Company as confirmed by this letter.

 

    	2

    	 

    

 

		2.	Duties

 

		2.1	As a director of the Company you will be expected to exercise the general fiduciary duties and
duties of care and loyalty as provided under the laws of the Cayman Islands and provide such advice and services as the Board may
reasonably require.

 

		2.2	The Board as a whole is collectively responsible for the success of the Company. The Board’s
role is to:

 

		2.2.1	provide entrepreneurial leadership of the Company within a framework of prudent and effective controls,
which enable risk to be assessed and managed;

 

		2.2.2	set the Group’s strategic aims, develop the necessary financial and human resources for the
Company to meet its objectives and review management performance; and

 

		2.2.3	set the Company’s values and standards in light of its obligations to its shareholders and
others.

 

		2.3	In your role as a non-executive director, you shall be required to:

 

		2.3.1	constructively challenge and contribute to the development of the Group’s strategy;

 

		2.3.2	scrutinize the performance of management in meeting agreed goals and objectives and monitor the
reporting of performance;

 

		2.3.3	satisfy yourself that financial information is accurate and that financial controls and systems
of risk management are appropriate, robust and defensible;

 

		2.3.4	use your best efforts to attend all meetings of the Board and the annual and all other meetings
of the shareholders of the Company;

 

		2.3.5	at all times comply with the Memorandum and Articles of Association of the Company, each as the
same may be amended or restated from time to time;

 

		2.3.6	abide by your fiduciary duties as a director of the Company;

 

		2.3.7	diligently perform your duties;

 

		2.3.8	immediately report your own wrongdoing or the wrongdoing or proposed wrongdoing of any other employee
or director of the Company of which you become aware to the Chairman of the Board; and

 

		2.3.9	comply with the terms of the BeyondSpring Inc. Code of Ethics and Business Conduct adopted by the
Board (a copy of which is enclosed herewith) and any other code of practice issued by the Company from time to time relating to
dealing in the Company’s securities.

 

    	3

    	 

    

		2.4	In addition, your duties require that you shall:

 

		2.4.1	promote the highest standards of integrity, probity and corporate governance throughout the Company,
particularly at Board level;

 

		2.4.2	use your best efforts to ensure that the Board receives accurate, timely and clear information;

 

		2.4.3	use your best efforts to ensure effective communication with shareholders;

 

		2.4.4	use your best efforts to facilitate the effective contribution of non-executive directors and promote
constructive relations are maintained between the executive and non-executive directors;

 

		2.4.5	at the request of the Company, serve on committees of the Board as shall be agreed between you
and the Chairman of the Board.

 

		3.	Time Commitment

 

You shall work such hours per week over
the term of Your Appointment as are necessary for the proper performance of your duties as a non-executive director of the Company.
You will be required to attend Board meetings, the annual shareholders meeting, Board dinners, meetings with non-executive directors
and training meetings. Some of these meetings may involve travel. You confirm that you are able to allocate sufficient time to
the Company to discharge your responsibilities effectively and should obtain the agreement of the Chairman of the Board prior to
accepting any additional commitments that might adversely affect your ability to perform your role as a director of the company.

 

		4.	Fees

 

You will be entitled to certain cash fees
in connection with your services as set forth below:

 

	i.	Annual retainer fee	$30,000 in cash
	ii.	Annual retainer fee for a director acting as Chairman of either the Compensation Committee, the Nominating and Corporate Governance Committee, or the Audit Committee, if so appointed	$3,750 in cash

 

The annual retainer fees are paid on a
fiscal year basis and shall be prorated for any partial year of Board service. The fees and the terms prescribing the frequency
of payment are subject to change at the sole discretion of the Compensation Committee of the Board. Upon termination of your Appointment,
you will (if applicable) be paid your annual retainer fee on a pro-rata basis, to the extent unpaid up to the Termination Date.

 

    	4

    	 

    

Beginning in 2017, you will receive an
annual award of restricted ordinary shares (“Restricted Shares”) with a grant date value of $30,000. Such Restricted
Shares will be issued under the Company’s 2017 Omnibus Incentive Plan or a successor plan (the “Stock Plan”)
and will vest in three equal installments, with the first installment vesting upon the first anniversary of the grant date, the
second installment vesting on the second anniversary of the grant date and the final remaining installment vesting on the third
anniversary of the grant date, subject in each case to your continued service as a director of the Company through the applicable
vesting date. Beginning in 2017, if you are appointed to serve as the Chairperson of either the Audit Committee, the Compensation
Committee or the Nominating and Corporate Governance Committee, you will receive an additional annual award of Restricted Shares
with a grant date value of $3,750 for each Chairperson position held. Such Restricted Shares will be issued under the Stock Plan
and will vest in three equal installments, with the first installment vesting upon the first anniversary of the grant date, the
second installment vesting on the second anniversary of the grant date and the final remaining installment vesting on the third
anniversary of the grant date, subject in each case to your continued service as a director of the Company through the applicable
vesting date.

 

You acknowledge that the Company may determine
to change any equity compensation program and this Letter shall in no way be deemed to be a guarantee of future equity compensation
programs. Any grant of Restricted Shares made to you will be subject to the terms and conditions of the Stock Plan and the applicable
restricted share award agreement memorializing such grant.

 

		5.	Term of Office

 

Your Appointment will commence on the date
hereof, and shall continue unless or until your successor is elected and qualified or until your earlier resignation or removal
in accordance with the Company’s articles of association. By your countersignature hereto you agree that you will give not
less than sixty (60) days’ notice (or such lesser period if agreed by the Board) in writing to the Company in the event you
wish to resign prior to the expiration of your term or in the event you do not wish to stand for re-election at the Company’s
annual general meeting.

 

By your counter-signature hereto, you acknowledge
that your continuation in office is subject to the laws of the Cayman Islands and the Memorandum and Articles of Association of
the Company, each as the same may be amended or restated from time to time. Any term renewal is subject to the review of the Board
and re-election at the Company’s annual general meeting. Notwithstanding any expectations, there is no right to re-nomination
by the Board.

 

On termination of Your Appointment for
whatever reason you will promptly return to the Company all documents, records, keys, correspondence or other items in your possession
or under your control which relate in any way to the business or affairs of, or are the property of, the Company or any Group,
including electronic records and all copies thereof, regardless of the medium upon or in which such copies are stored or held.
In addition, you will cease to use the Company’s facilities and cease to hold yourself out as being a director of the Company.

 

		6.	Expenses

 

The Company shall reimburse you in respect
of all reasonable travelling, hotel and other out of pocket expenses properly and necessarily incurred by you in or about the performance
of your duties under this Agreement, in accordance with Company policies in effect from time to time and subject to the production
(if requested) of any receipts, vouchers and other supporting documentation that the Company shall reasonably require.

    	5

    	 

    

 

		7.	Confidentiality

 

		7.1	Both during your service on the Board and after the Termination Date, you agree and will undertake
to maintain any and all Confidential Information in strict confidence at all times and you shall not, directly or indirectly, publish,
reveal or otherwise disclose or make available any such Confidential Information to any person or entity and will not use Confidential
Information for any purpose. Notwithstanding the foregoing, these obligations shall not apply to any Confidential Information that:

 

		7.1.1	is necessary for the proper and effective performance of your duties as a director of the Company
and then only with the prior written consent of the Company; and to a person who shall be subject to equivalent, express, written
confidentiality obligations to the Company or a Group Company;

 

		7.1.2	to the extent that such information is or (without default of your part) becomes generally available
to the public;

 

		7.1.3	to the extent that you shall be required to disclose the same by any applicable law or legally
binding order of any court, government, semi-governmental authority, administrative or judicial body, or a legally binding requirement
of a stock exchange or regulator; or

 

		7.1.4	to the extent the Company approved such release in a prior written consent.

 

		7.2	If you are required to make a disclosure as contemplated in clause 7.1.3:

 

		7.2.1	you must disclose only the minimum Confidential Business Information required to comply with the
applicable law, order or requirement; and

 

		7.2.2	before making such disclosure, you must:

 

		(a)	give the Company reasonable written notice of:

 

		(i)	the full circumstances of the requirement for disclosure arising; and

 

		(ii)	the Confidential Business Information which you propose to disclose; and

 

		(b)	consult with the Company as to the form of the disclosure.

 

		7.3	By your counter-signature hereto, you acknowledge that:

 

		7.3.1	the Company and each Group Company possess a valuable body of Confidential Business Information;

 

		7.3.2	the Company has given and will continue to give you access to Confidential Business Information
in order that you may carry out your duties hereunder;

 

		7.3.3	your duties include, without limitation, a duty of care and a duty of loyalty as provided under
the laws of the Cayman Islands;

 

    	6

    	 

    

		7.3.4	the disclosure of any Confidential Business Information other than as permitted in Clause 7.3 could
place Company and any impacted Group Company at a serious competitive disadvantage and could cause immeasurable (financial and
other) damage to the Businesses; and

 

		7.3.5	that the obligations of confidentiality assumed under the provisions of this clause 7 are reasonable
and necessary for the protection of the Group, the Businesses and the Confidential Business Information.

 

		8.	Other Interests and Restrictions

 

		8.1	It is accepted and acknowledged that you have business interests other than those of the Company
and that you have declared any potential conflicts that are apparent at present. If you become aware of any potential conflicts
of interest after the date hereof, these should be disclosed to the Chairman of the Board and company secretary or otherwise in
accordance with the articles of association of the Company as soon as you become aware thereof.

 

		8.2	By your counter-signature hereto, you agree and undertake that, during the term of Your Appointment,
you shall not, without the Company’s written permission, assume or hold any Material Interest in any person, firm or company
which:

 

		8.2.1	impairs or might reasonably be expected by the Board to impair your ability to act at all times
in the best interests of the Company; or

 

		8.2.2	requires or might reasonably be expected by the Board to require you to disclose any Confidential
Business Information in order to properly discharge your duties to or to further your interest in such person, firm or company.

 

		8.3	By your counter-signature hereto, you agree and undertake that you will not at any time after the
Termination Date, represent or hold yourself out or permit yourself to be represented or held out by any person, firm or company
as being in any way then currently connected with or interested in the Company or any Group Company other than (if such be the
case) as the holder of shares, options and/or warrants in the Company.

 

		8.4	By your counter-signature hereto, you agree and confirm that neither this letter, nor your or our
actions, past, present or future constitute a contract of employment and no employer-employee relationship exists or will exist
between the Company or any member of the Group and you and to indemnify and hold harmless the Company, its directors, officers,
employees and assignees harmless from and against any and all demands and/or claims addressed against the Company by you or on
your behalf, or any third party, in connection with any alleged employment relationship between the Company and you, or in connection
with any liability, obligation, debt or responsibility deriving from such relationship, including by virtue of any agreement, arrangement,
statute, extension order, custom or the like. You will be treated as an independent contractor for purposes of the Federal Insurance
Contributions Act, Federal Income Tax Withholding, the Employee Retirement Income Security Act, state unemployment or disability
insurance laws, and any other employment taxes or laws. In this regard, the Company will not make deductions from payments made
to you for taxes, which shall be your responsibility.

 

    	7

    	 

    

		8.5	Each of the provisions of clauses 8.2, 8.3 and 8.4 and (where applicable) the sub-clauses thereof
is independent and severable from the remaining provisions and enforceable accordingly. If any provision of the said clauses/sub-clauses
shall be unenforceable for any reason but would be enforceable if part of the wording thereof were deleted, it shall apply with
such deletions as may be necessary to make it enforceable.

 

		8.6	You have given the undertakings contained in this clause 8 to the Company itself and to the Company
as trustee for the benefit of each Group Company and will, at the request and cost of the Company, promptly enter into direct undertakings
with any Group Company which correspond to the undertakings in this clause 8.

 

		8.7	The Company agrees that each Material Interest that you assume or hold as of the date hereof is
hereby permitted.

 

		8.8	Notwithstanding anything herein to the contrary, pursuant to 18 U.S.C. § 1833(b), you will
not be held criminally or civilly liable under any U.S. federal or state trade secret law for the disclosure of a trade secret
of the Company that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly,
or to your attorney and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made
in a complaint or other document that is filed under seal in a lawsuit or other proceeding. If you file a lawsuit for retaliation
by the Company for reporting a suspected violation of law, you may disclose the trade secret to your attorney and use the trade
secret information in the court proceeding, if you (I) file any document containing the trade secret under seal, and (II) do not
disclose the trade secret, except pursuant to court order. Nothing herein is intended to conflict with 18 U.S.C. § 1833(b)
or create liability for disclosures of trade secrets that are expressly allowed by such section. Further, nothing in any agreement
you have with the Company shall prohibit or restrict you from making any voluntary disclosure of information or documents related
to any violation of law to any governmental agency or legislative body, or any self-regulatory organization, in each case, without
advance notice to the Company.

 

		9.	Independent Legal Advice

 

Occasions may arise when you consider that
you will need professional advice in connection with the performance of your duties as a director of the Company and you will be
able to consult the Company’s advisors for this purpose. Exceptional circumstances may occur when it may be appropriate for
you to seek such advice from independent advisors, at the Company’s expense. In such an event, you should, where reasonably
practical and not (in your reasonable judgment) prejudicial to the interests of the Company, consult with the Board or, if you
consider appropriate, the non-executive directors, prior to such advice being sought or expense being incurred.

 

		10.	Governing Law and Jurisdiction

 

This Letter shall be governed by and shall
be interpreted in accordance with the laws of the State of New York, without giving effect to its choice of law legislation. The
parties irrevocably submit to the non-exclusive jurisdiction of the U.S. Federal and New York State courts in the Borough of Manhattan,
the City of New York in relation to all matters arising out of or in connection with this appointment letter.

 

[Signature Page Follows]

 

    	8

    	 

    

On a more personal note, I want to tell
you how pleased I am that you are joining the BeyondSpring Board of Directors. I know that I speak for the other directors in saying
that we look forward to your leadership and contributions as a director. I would greatly appreciate if you would confirm your acceptance
of the terms of your appointment by signing and returning this Letter.

 

With kind regards,

 

	 	 	 
	 	 	 

                                                         

 

Duly authorized for and on behalf of
the Board

 

I hereby acknowledge the above terms and
agree and undertake in the above terms.

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	Date

  

 

    	9Exhibit 10.17

 

FORM OF SHARE SUBSCRIPTION AGREEMENT

 

This SHARE SUBSCRIPTION
AGREEMENT (this “Agreement”) is entered into as of [●], 2017, by and between BeyondSpring Inc., a Cayman Islands
company (the “Company”), and the undersigned (the “Investor”).

 

WHEREAS, the Company
intends to offer and sell ordinary shares, par value $0.0001 per ordinary share, of the Company (the “Ordinary Shares”)
to the public and list the Ordinary Shares on the NASDAQ Capital Market (the “IPO”).

 

WHEREAS, concurrently
with the IPO, the Company desires to issue, sell and convey that number of Ordinary Shares determined by dividing $[●] million
by the price to the public for one Ordinary Share offered in the IPO, rounded to the nearest whole number, to the Investor, and
the Investor desires to purchase such Ordinary Shares from the Company, pursuant to and in accordance with the terms and conditions
of this Agreement (such Ordinary Shares to be purchased hereunder, the “Shares”); and

 

NOW, THEREFORE, in consideration
of the foregoing, the representations, warranties, covenants and agreements contained herein, and for other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound hereby, the parties hereto agree
as follows:

 

1.     
Representations, Warranties and Agreements of the Company. The Company represents, warrants and agrees that:

 

(a)           
In connection with the IPO, a Registration Statement (as defined below) relating to the offer and sale of Ordinary Shares
(other than the Shares) has (i) been prepared by the Company in conformity with the requirements of the Securities Act of
1933, as amended (the “Securities Act”), and the rules and regulations of the Securities and Exchange Commission (the
“Commission”) thereunder; and (ii) been filed with the Commission under the Securities Act. As used in this Agreement:

 

		1.	“Preliminary Prospectus” means the most recent preliminary prospectus relating to the Ordinary Shares included
in the Registration Statement prior to the date hereof; and

 

		2.	“Registration Statement” means the registration statement on Form F-1 (File No. 333-214610),
as amended as of immediately prior to the date hereof, including the Preliminary Prospectus and all exhibits to such registration
statement.

 

(b)           The Company and each of its subsidiaries have been duly organized, is validly existing and in good standing (where such
concept is applicable) under the laws of the jurisdiction of its incorporation or organization and is duly qualified to do business
and in good standing as a foreign corporation or other business entity in each jurisdiction in which its ownership or lease of
property or the conduct of its businesses requires such qualification, except where the failure to be so qualified or in good standing
would not, in the aggregate, reasonably be expected to have a material adverse effect on the condition (financial or otherwise),
results of operations, shareholders’ equity, properties, business or prospects of the Company and its subsidiaries taken
as a whole (a “Material Adverse Effect”). The Company and each of its subsidiaries have all power and authority necessary
to own or hold its properties and to conduct the businesses in which it is engaged.

 

(c)           The Shares to be issued and sold by the Company to the Investor hereunder have been duly authorized and, upon payment and
delivery in accordance with this Agreement, will be validly issued, fully paid and non-assessable, will conform in all material
respects to the description thereof contained in the Preliminary Prospectus, will be issued in compliance with U.S. federal and
state securities laws and the laws of the Cayman Islands and will be free of statutory and contractual preemptive rights, rights
of first refusal and similar rights.

 

    	 

    	 

    

(d)           The Company has all requisite corporate power and authority to execute, deliver and perform its obligations under this Agreement.
This Agreement has been duly and validly authorized, executed and delivered by the Company and, when executed and delivered by
the Investor, will constitute valid and legally binding obligations of the Company, enforceable in accordance with its terms, except
as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general
application affecting enforcement of creditors’ rights generally, and as limited by laws relating to the availability of
specific performance, injunctive relief or other equitable remedies, and except to the extent Section 8 hereof is found to violate
public policy.

 

(e)           The issue and sale of the Shares, the execution, delivery and performance of this Agreement by the Company, the consummation
of the transactions contemplated hereby and the application of the proceeds from the sale of the Shares as described under “Use
of Proceeds” in the Preliminary Prospectus will not (i) conflict with or result in a breach or violation of any of the
terms or provisions of, impose any lien, charge or encumbrance upon any property or assets of the Company and its subsidiaries,
or constitute a default under, any indenture, mortgage, deed of trust, loan agreement, license, lease or other agreement or instrument
to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which
any of the property or assets of the Company or any of its subsidiaries is subject; (ii) result in any violation of the provisions
of the certificate of incorporation and memorandum and articles of association (or similar organizational documents) of the Company
or any of its subsidiaries; or (iii) result in any violation of any statute or any judgment, order, decree, rule or regulation
of any court or governmental agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties
or assets, except, with respect to clauses (i) and (iii), conflicts or violations that would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect.

 

(f)           No consent, approval, authorization or order of, or filing, registration or qualification with, any court or governmental
agency or body having jurisdiction over the Company or any of its subsidiaries or any of their properties or assets is required
for the issue and sale of the Shares, the execution, delivery and performance of this Agreement by the Company, the consummation
of the transactions contemplated hereby and the application of the proceeds from the sale of the Shares as described under “Use
of Proceeds” in the Preliminary Prospectus.

 

(g)           Neither the Company nor any of its subsidiaries is, and as of the applicable Closing Date (as defined herein) and, after
giving effect to the offer and sale of the Shares and the application of the proceeds therefrom as described under “Use of
Proceeds” in the Preliminary Prospectus, none of them will be, (i) an “investment company” or a company “controlled”
by an “investment company” within the meaning of the Investment Company Act of 1940, as amended (the “Investment
Company Act”), and the rules and regulations of the Commission thereunder, or (ii) a “business development company”
(as defined in Section 2(a)(48) of the Investment Company Act).

 

(h)           The Company is a “foreign issuer” (as defined in Regulation S under the Securities Act).

 

(i)            To the Company’s knowledge, neither the Company nor any of its affiliates (as defined in Regulation 501 under the
Securities Act) nor any person acting on its or their behalf has engaged in any directed selling efforts (as defined in Regulation
S under the Securities Act) in connection with the offering of the Shares.

 

2.     
Representations, Warranties and Agreements of the Investor. The Investor represents, warrants and agrees that:

 

(a)           To the extent the Investor is an entity, it is duly organized, validly existing and in good standing under the laws of the
jurisdiction of its organization, and has all requisite power and authority to execute, deliver and perform its obligations under
this Agreement. This Agreement has been duly and validly authorized, executed and delivered by the Investor and, when executed
and delivered by the Company, will constitute valid and legally binding obligations of the Investor, enforceable in accordance
with its terms, except as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any
other laws of general application affecting enforcement of creditors’ rights generally, and as limited by laws relating to
the availability of specific performance, injunctive relief or other equitable remedies.

 

    	2

    	 

    

(b)           The Investor has had an opportunity to discuss the Company’s business, management, financial affairs and the terms
and conditions of the offering of the Shares with the Company’s management. The foregoing, however, does not limit or modify
the representations and warranties of the Company in Section 1 of this Agreement or the right of the Investor to rely thereon.

 

(c)           The Investor is not a U.S. person (as such term is defined in Regulation S under the Securities Act) and is not acquiring
the Shares for the account or benefit of any U.S. person.

 

(d)           The Investor understands and acknowledges that (i) the Shares have not been registered under the Securities Act, are being
sold in reliance upon an exemption from registration afforded by Regulation S and that the Shares have not been registered with
any state securities commission or authority and that the Company is relying upon the truth and accuracy of, and the Investor’s
compliance with, the representations, warranties, agreements, acknowledgements and understandings of the Investor set forth herein
in order to determine the availability of such exemption and the eligibility of the Investor to acquire the Shares, and (ii) the
Investor will not be afforded the protection of Section 11 of the Securities Act and that, pursuant to Regulation S, the Shares
may not be transferred, sold or otherwise exchanged unless in compliance with the provisions of Regulation S or Rule 144 under
the Securities Act, pursuant to registration under the Securities Act, or pursuant to an available exemption thereunder.

 

(e)           The Investor was not formed specifically for the purpose of acquiring the Shares purchased pursuant to this Agreement.

 

(f)           The Investor understands, acknowledges and agrees that it must bear the economic risk of its investment in the Shares for
an indefinite period of time and that prior to any such offer or sale, the Company may require, as a condition to effecting a transfer
of the Shares, an opinion of counsel, acceptable to the Company, as to the registration or exemption therefrom under the Securities
Act and any state securities acts, if applicable.

 

(g)           The transactions contemplated by this Agreement have neither been pre-arranged with a purchaser who is in the United States
or who is a U.S. person, nor are they part of a plan or scheme to evade the registration provisions of the U.S. federal securities
laws.

 

(h)           The offer leading to the sale evidenced hereby was made in an “offshore transaction.” For purposes of Regulation
S, Investor understands that an “offshore transaction” as defined under Regulation S is any offer or sale not made
to a person in the United States and either (i) at the time the buy order is originated, the purchaser is outside the United States,
or the seller or any person acting on his behalf reasonably believes that the purchaser is outside the United States; or (ii) for
purposes of (A) Rule 903 of Regulation S, the transaction is executed in, or on or through a physical trading floor of an established
foreign exchange that is located outside the United States or (B) Rule 904 of Regulation S, the transaction is executed in, on
or through the facilities of a designated offshore securities market, and neither the seller nor any person acting on its behalf
knows that the transaction has been prearranged with a buyer in the United States.

 

(i)            Neither the Investor nor any affiliate or any person acting on the Investor’s behalf, has made or is aware of any
“directed selling efforts” in the United States, which is defined in Rule 902(c) of Regulation S to be any activity
undertaken for the purpose of, or that could reasonably be expected to have the effect of, conditioning the market in the United
States for any of the Shares being offered hereby in reliance on Regulation S.

 

(j)            The Investor understands that the Company is the seller of the Shares which are the subject of this Agreement, and that,
for purposes of Regulation S, a “distributor” is any underwriter, dealer or other person who participates, pursuant
to a contractual arrangement, in the distribution of securities offered or sold in reliance on Regulation S and that an “affiliate”
is any partner, officer, director or any person directly or indirectly controlling, controlled by or under common control with
any person in question. The Investor agrees that the Investor will not act as a distributor, either directly or through any affiliate,
nor shall it sell, transfer, hypothecate or otherwise convey the Shares other than to a non-U.S. Person.

 

    	3

    	 

    

(k)           The Investor acknowledges that each certificate, instrument, or book entry representing (i) the Shares and (ii) any other
securities issued in respect of the securities referenced in clauses (i) upon any stock split, stock dividend, recapitalization,
merger, consolidation, or similar event, shall be notated with a legend substantially in the following form:

 

THE SECURITIES REPRESENTED HEREBY
HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED,
OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION OF THE SECURITIES ACT OF 1933.

 

The Investor consents
to the Company making a notation in its records and giving instructions to any transfer agent of the Shares or such securities
in order to implement the restrictions on transfer set forth in this Agreement. Upon receipt of a request from the Investor, the
foregoing legend shall be removed from the certificate, instrument or book entry evidencing the Shares and the Company shall, or
shall cause its transfer agent to, issue a certificate or certificates evidencing all or a portion of the Shares, as requested
by the Investor, without such legend if: (i) such Shares have been resold under an effective registration statement under
the Securities Act, (ii) the Investor has provided the Company and its transfer agent with reasonable assurances that such Shares
have been transferred in compliance with Rule 144 or Regulation S or (iii) the Investor has provided the Company and its transfer
agent with an opinion of counsel reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably
satisfactory to the Company, stating that such Shares may lawfully be transferred without registration under the Securities Act
and that the foregoing legend may be removed following such transfer.  

 

3.     
Purchase of the Shares by the Investor. On the basis of the representations, warranties and covenants contained in, and
subject to the terms and conditions of, this Agreement, the Company agrees to sell the Shares to the Investor, and the Investor
agrees to purchase the Shares from the Company. The Company is not obligated to deliver any of the Shares to be delivered on the
Closing Date, except upon payment for all such Shares to be purchased on the Closing Date as provided herein.

 

4.     
Escrow. Before the Closing Date, the Investor shall deposit the sum equal to the purchase price of the Shares (“Escrow
Amount”) by wire transfer of immediately available funds into an account designated by Signature Bank to be held and distributed
in accordance with the terms of the form of Escrow Agreement attached to this Agreement as Exhibit A (“Escrow Agreement”).

 

5.     
Delivery of and Payment for the Shares. Delivery of and payment for the Shares shall be made on the closing date of the
offer and sale of Ordinary Shares pursuant to the Registration Statement (the “Closing Date”). Delivery of the Shares
shall be made to the Investor against payment by the Investor of the purchase price of the Shares to the Company upon the release
of Escrow Amount in such manner as provided in the Escrow Agreement. Time shall be of the essence, and delivery at the time and
place specified pursuant to this Agreement is a further condition of the obligation of the Investor hereunder.

 

6.     
Conditions of the Investor’s Obligations. The obligations of the Investor hereunder are subject to the accuracy, when
made and on the Closing Date, of the representations and warranties of the Company contained herein, to the performance by the
Company of its obligations hereunder and to the closing of the IPO.

 

7.     
Registration of Shares. If the Company proposes to register its Ordinary Shares under the Securities Act on a form
which would permit registration of the Shares for sale to the public, or publicly sell under a shelf registration statement Ordinary
Shares, for its own account and/or for the account of any other person, the Company shall have the option to (a) give notice thereof
to the Investor and (b) in its sole discretion, include in such registration all or any of the Shares with respect to which the
Company has received written requests for inclusion therein within five (5) business days after notice has been given to the Investor
at the address provided in Section 10 hereof. Notwithstanding the foregoing, in case of an underwritten offering, the Company shall
have the right to reduce the amount of Shares to be included in such offering to the amount recommended by the managing underwriter
or underwriters, if in their good faith opinion that the total amount of securities that the Investor, the Company and any other
persons having rights to participate in such registration, intend to include in such offering is such as to adversely affect the
success of such offering.

 

    	4

    	 

    

8.     
Indemnification.

 

(a)   
The Company hereby agrees that its shall indemnify, defend and hold harmless the Investor, its affiliates and each of their
respective, directors, officers, employees, shareholders, representatives and agents (“Indemnified Parties”) from,
against and in respect of any damages, losses, charges, liabilities, claims demands, actions, suits, proceedings, payments, judgments,
settlements, assessments, deficiencies, interest and costs and expenses (“Losses”) imposed on, sustained, incurred
or suffered by or asserted against any of the Indemnified Parties (whether in respect of third party claims, claims between the
parties hereto, or otherwise) directly or indirectly relating to or arising out of any breach by the Company of any of representations,
warranty or agreement made by it in this Agreement.

 

(b)  
The Company further agrees to indemnify each of the Indemnified Parties against any all Losses incurred by such Indemnified
Party related to or arising from to efforts to enforce or protect its rights under this Agreement, or the exercise of its rights
or powers consequent upon or arising out of any breach of this Agreement.

 

(c)   
The remedies set forth in this Section 8 shall be without prejudice to all other rights and remedies that an Indemnified
Party may have under applicable law and shall not be the sole and exclusive remedies of any Indemnified Party for any Loss suffered
hereunder. Each Indemnified Party shall be entitled to pursue any remedy that is available to it under applicable law.

 

9.     
Termination. The obligations of the parties under this Agreement shall terminate upon the earlier of (i) April 25, 2017
and (ii) the mutual written consent of the parties.

 

10.    
Notices. All statements, requests, notices and agreements hereunder shall be in writing, and:

 

(a)   
if to the Investor, shall be delivered or sent by mail, facsimile transmission or email to the address set forth on the
signature page hereto;

 

(b)  
if to the Company, shall be delivered or sent by mail, facsimile transmission or email to:

 

BeyondSpring Inc.

28 Liberty Street, 39th Floor

New York, New York 10005

Facsimile: (646) 882-4228

Email: lan.huang@beyondspringpharma.com

Attention: Lan Huang

 

With a copy (which shall not
constitute notice) to:

 

Skadden, Arps, Slate, Meagher &
Flom LLP

Four Times Square

New York, New York 10036

Facsimile: (917) 777-3416

Email: andrea.nicolas@skadden.com

Attention: Andrea L. Nicolas

 

Any such statements, requests, notices
or agreements shall take effect at the time of receipt thereof.

 

    	5

    	 

    

11.    
Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the Investor,
the Company and their respective successors. This Agreement and the terms and provisions hereof are for the sole benefit of only
those persons, except that the representations, warranties, indemnities and agreements of the Company contained in this Agreement
shall also be deemed to be for the benefit of the Indemnified Parties. Nothing in this Agreement is intended or shall be construed
to give any person, other than the persons referred to in this Section 11, any legal or equitable right, remedy or claim under
or in respect of this Agreement or any provision contained herein.

 

12.    
Survival. The respective indemnities, representations, warranties and agreements of the Company and the Investor contained
in this Agreement pursuant to this Agreement, shall survive the delivery of and payment for the Shares and shall remain in full
force and effect, regardless of any investigation made by or on behalf of any of them or any person controlling any of them.

 

13.    
Definition of the Terms “Business Day”, “Affiliate” and “Subsidiary”. For purposes of
this Agreement, (a) “business day” means each Monday, Tuesday, Wednesday, Thursday or Friday that is not a day on which
banking institutions in New York are generally authorized or obligated by law or executive order to close, and (b) “affiliate”
and “subsidiary” have the meanings set forth in Rule 405 under the Securities Act.

 

14.    
Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without
regard to conflict of laws principles (other than Section 5-1401 of the General Obligations Law).

 

15.    
Submission to Jurisdiction. The Company hereby submits to the non-exclusive jurisdiction of the U.S. federal and New York
state courts in the Borough of Manhattan, The City of New York in any suit or proceeding arising out of or relating to this Agreement
or the transactions contemplated hereby. The parties hereby irrevocably and unconditionally waive any objection to the laying of
venue of any lawsuit, action or other proceeding in such courts, and hereby further irrevocably and unconditionally waive and agree
not to plead or claim in any such court that any such lawsuit, action or other proceeding brought in any such court has been brought
in an inconvenient forum. Each party hereto hereby irrevocably waives personal service of process and consents to process being
served in any such lawsuit, action or other proceeding by mailing a copy thereof via registered or certified mail or overnight
delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed
to limit in any way any right to serve process in any manner permitted by law.

 

16.    
Waiver of Immunity. With respect to any suit or proceeding arising out of or relating to this Agreement or the transactions
contemplated hereby, each party irrevocably waives, to the fullest extent permitted by applicable law, all immunity (whether on
the basis of sovereignty or otherwise) from jurisdiction, service of process, attachment (both before and after judgment) and execution
to which it might otherwise be entitled, and with respect to any such suit or proceeding, each party waives any such immunity in
any court of competent jurisdiction, and will not raise or claim or cause to be pleaded any such immunity at or in respect of any
such suit or proceeding, including, without limitation, any immunity pursuant to the U.S. Foreign Sovereign Immunities Act of 1976,
as amended.

 

    	6

    	 

    

17.    
Judgment Currency. The obligation of the Company in respect of any sum due to the Investor or any other Indemnified Party
under this Agreement shall, notwithstanding any judgment in a currency other than U.S. dollars or any other applicable currency
(the “Judgment Currency”), not be discharged until the first business day, following receipt by such Indemnified Party
of any sum adjudged to be so due in the Judgment Currency, on which (and only to the extent that) such Indemnified Party may in
accordance with normal banking procedures purchase U.S. dollars or any other applicable currency with the Judgment Currency; if
the U.S. dollars or other applicable currency so purchased are less than the sum originally due to such Indemnified Party hereunder,
the Company agrees, as a separate obligation and notwithstanding any such judgment, to indemnify such Indemnified Party against
such Loss. If the U.S. dollars or other applicable currency so purchased are greater than the sum originally due to such Indemnified
Party hereunder, such Indemnified Party agrees to pay to the Company an amount equal to the excess of the U.S. dollars or other
applicable currency so purchased over the sum originally due to such Indemnified Party hereunder.

 

18.    
Waiver of Jury Trial. The company and the investor hereby irrevocably waive, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating to this agreement or the transactions
contemplated hereby.

 

19.    
Counterparts. This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart,
the executed counterparts shall each be deemed to be an original but all such counterparts shall together constitute one and the
same instrument.

 

20.    
Headings. The headings herein are inserted for convenience of reference only and are not intended to be part of, or to affect
the meaning or interpretation of, this Agreement.

 

[Signature Page Follows]

 

    	7

    	 

    

IN WITNESS WHEREOF,
the parties hereto have caused this Agreement to be executed on the date first above written.

 

	 	BeyondSpring Inc.
	 	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

    	 

    	 

    

	 	[●]
	 	 	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 
	 	 	 	 
	 	Address:
	 	Facsimile:
	 	Email:
	 	Attention:

 

    	 

    	 

    

Exhibit A

 

[Form of Escrow Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00267-of-00352.parquet"}]]